A new drug being tested for hypertrophic cardiomyopathy changed the structure of the heart in a new report from a clinical trial.

From moderate-risk TAVR to PCSK9 inhibitors to exercise in HCM, the American College of Cardiology’s annual Scientific Session brought advancements across many areas of cardiology.

Patients with hypertrophic cardiomyopathy are urged to take it easy. But new research shows they might benefit from moderate aerobic exercise.